세계의 두개내 치료제 전달 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 치료별, 적응증별, 지역별
Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
상품코드:1452672
리서치사:Fairfield Market Research
발행일:2024년 03월
페이지 정보:영문 168 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 두개내 치료제 전달 시장 규모는 전례없는 성장을 이루려고 합니다. 이 시장은 2024년에 22억 달러에 달할 것으로 보이고, 향후 10년간 CAGR 9%로 급성장할 전망이며, 2031년에는 40억 달러라는 경이적인 규모에 이를 것으로 예측되고 있습니다. 이 급증은 신경학의 혁신적인 치료에 대한 수요가 증가하고 세계 신경 질환의 유병률이 증가하는 것을 반영합니다.
2021년 세계 재생 의료 시장의 약 6.1%를 차지하는 두개내 치료제 전달은 환자 관리를 변화시키는 최전선에 서 있습니다. 세포, 유전자, 효소의 대체 요법에 중점을 둔 이 분야는 무수한 질병의 치료에 새로운 새벽을 약속하고 기존의 치료법으로는 불충분했던 부분에 희망을 부여합니다.
2018년부터 2023년까지, 특히 세포요법 및 유전자요법의 영역에서 두개내 치료제 전달법의 인기와 효능이 현저하게 상승하였습니다. 이 패러다임 교대는 Bristol Myers Squibb, Gilead Sciences & Company, Xcell Biosciences Inc.와 같은 바이오 의약품 선두의 광범위한 조사와 협력에 의해 지원되며 질병 관리 및 예방에 대한 혁신적인 접근법을 강조합니다. 전략적 인수와 제휴를 통해 이러한 주요 기업들이 우수성을 추구함으로써 업계에 새로운 벤치마크가 탄생하고 있습니다.
본 보고서에서는 세계의 두개내 치료제 전달 시장에 대해 조사했으며, 시장 개요와 함께 치료별, 적응증별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 정의 및 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나와 러시아의 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 두개내 치료제 전달 시장 전망(2018-2031년)
세계의 두개내 치료 딜리버리 시장 전망 : 치료별, 금액(10억 달러)(2018-2031년)
세계의 두개내 치료 딜리버리 시장 전망 : 적응증별, 금액(10억 달러)(2018-2031년)
세계의 두개내 치료 딜리버리 시장 전망 : 지역별, 금액(10억 달러)(2018-2031년)
제4장 북미의 두개내 치료제 전달 시장 전망(2018-2031년)
제5장 유럽의 두개내 치료제 전달 시장 전망(2018-2031년)
제6장 아시아태평양의 두개내 치료제 전달 시장 전망(2018-2031년)
제7장 라틴아메리카의 두개내 치료제 전달 시장 전망(2018-2031년)
제8장 중동 및 아프리카의 두개내 치료제 전달 시장 전망(2018-2031년)
제9장 경쟁 구도
치료법 및 적응증별 히트맵
기업의 시장 점유율 분석(2023년)
경쟁력 대시보드
기업 프로파일
Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics
제10장 부록
AJY
영문 목차
영문목차
The global intracranial therapeutic delivery market is poised for unprecedented growth. According to a comprehensive market analysis, the sector, valued at US$ 2.2 billion in 2024, is projected to burgeon at a compound annual growth rate (CAGR) of 9% over the next decade, culminating in a staggering US$ 4 billion by 2031. This surge reflects the increasing demand for innovative treatments in neurology and the rising prevalence of neurological disorders worldwide.
Intracranial Therapeutic Delivery: A Pillar of Regenerative Medicine
Accounting for approximately 6.1% of the global regenerative medicine market in 2021, intracranial therapeutic delivery stands at the forefront of transforming patient care. With a significant emphasis on cell, gene, and enzyme replacement therapies, this sector promises a new dawn in the treatment of a myriad of conditions, offering hope where traditional modalities fall short.
A Decade in Review: Triumphs and Innovations
The period from 2018 to 2023 has witnessed a notable ascent in the popularity and efficacy of intracranial therapeutic delivery methods, especially in the realms of cell and gene therapy. This paradigm shift, underpinned by extensive research and collaboration among biopharmaceutical giants such as Bristol Myers Squibb, Gilead Sciences & Company, and Xcell Biosciences Inc., underscores a transformative approach to disease management and prevention. The pursuit of excellence by these key players, through strategic acquisitions and partnerships, is setting new benchmarks in the industry.
Market Drivers: A Confluence of Innovation and Opportunity
The market's trajectory is notably influenced by the burgeoning pipeline of cell, gene, and enzyme replacement therapies, which account for a substantial portion of the pharmaceutical industry's research focus. With over 750 trials and more than 200 investigational new drug applications anticipated by the U.S. FDA, the sector is on the cusp of delivering groundbreaking treatments to patients across the globe.
Moreover, a tangible shift towards regenerative therapies over conventional drug-based treatments is reshaping the landscape. These advancements, coupled with supportive government policies, especially in emerging economies, herald a new era of healthcare possibilities.
Challenges and Constraints: Navigating Through Uncertainties
Despite the optimistic outlook, the market faces hurdles, primarily due to the high costs associated with these advanced therapies. The financial implications for patients and healthcare systems, along with a lack of comprehensive reimbursement policies, present significant challenges. Addressing these concerns is crucial for ensuring the accessibility and sustainability of intracranial therapeutic delivery methods.
Geographical Insights: Key Markets and Emerging Players
United States: Leading the charge with a 36.4% market share, the U.S. is a hotbed for R&D, bolstered by robust government support and regulatory frameworks.
Germany: With a quarter share of the European market, Germany's robust healthcare expenditure and thriving biopharmaceutical landscape make it a key player in the sector.
United Kingdom: The U.K.'s commitment to regenerative medicine and its significant contribution to the European advanced therapeutic medicinal products (ATMP) sector underscore its pivotal role in the market's growth.
South Korea: Demonstrating rapid progress, South Korea's strategic investments in biopharma and biotech are unlocking new possibilities in intracranial therapeutic delivery.
The Competitive Landscape: Fostering Innovation and Collaboration
The market's future is shaped by strategic collaborations, mergers, and acquisitions among leading firms. Innovations and product launches are critical for maintaining competitive advantage and addressing the evolving needs of patients worldwide. Notable developments, such as ElevateBio's lentiviral vector production platform and the collaboration between Biogen and Ginkgo Bioworks, highlight the industry's commitment to revolutionizing intracranial therapeutic delivery.
Key Companies Profiled
Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics
Segmentation of Intracranial Therapeutic Delivery Industry
Intracranial Therapeutic Delivery Market by Therapy:
Cell-based Therapy
Gene Therapy
Enzyme Replacement Therapy
Intracranial Therapeutic Delivery Market by Indication:
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Batten Disease
Amyotrophic Lateral Sclerosis
Intracranial Therapeutic Delivery Market by Region:
U.S. Intracranial Therapeutic Delivery Market
Europe Intracranial Therapeutic Delivery Market
Rest of the World (ROW) Intracranial Therapeutic Delivery Market
Table of Contents
1. Executive Summary
1.1. Global Intracranial Therapeutic Delivery Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031
3.1. Global Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Cell-based Therapy
3.1.1.2. Gene Therapy
3.1.1.3. Enzyme Replacement Therapy
3.2. Global Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Spinal Muscular Atrophy (SMA)
3.2.1.2. Multiple Sclerosis
3.2.1.3. Batten Disease
3.2.1.4. Amyotrophic Lateral Sclerosis
3.3. Global Intracranial Therapeutic Delivery Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031
4.1. North America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Cell-based Therapy
4.1.1.2. Gene Therapy
4.1.1.3. Enzyme Replacement Therapy
4.2. North America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Spinal Muscular Atrophy (SMA)
4.2.1.2. Multiple Sclerosis
4.2.1.3. Batten Disease
4.2.1.4. Amyotrophic Lateral Sclerosis
4.3. North America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
4.3.1.2. U.S. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
4.3.1.3. Canada Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
4.3.1.4. Canada Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
